Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia

Bibliography

• Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13
   PubMed Web of Science ®Google Scholar
• Stasi R, Proven D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504-22
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-13
   PubMed Web of Science ®Google Scholar
• Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-74
   PubMed Web of Science ®Google Scholar
• Stasi R, Amadori S, Osborn J, et al. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006;3:e24
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med 2000;160:1630-8
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511-21
   PubMed Web of Science ®Google Scholar
• George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura in adults. Curr Opin Haematol 2007;14:535-56
   PubMedGoogle Scholar
• Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532-7
   PubMed Web of Science ®Google Scholar
• Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012;120:3670-6
   PubMed Web of Science ®Google Scholar
• Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adult. Curr Opin Haematol 2007;14:535-56
   PubMed Web of Science ®Google Scholar
• Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28:249-55
   PubMed Web of Science ®Google Scholar
• Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28:249-55
   PubMed Web of Science ®Google Scholar
• Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood 1978;51:771-9
   PubMed Web of Science ®Google Scholar
• Bae SH, Ryoo HM, Lee W, et al. High dose dexamethasone vs. conventional dose prednisolone in adults with immune thrombocytopenia: a prospective multicenter phase II trial. Amer Soc of Haem Congress [abstract]. Blood 2010;116:abstract 3687
   Google Scholar
• Balagué C, Vela S, Targarona EM, et al. Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura. Surg Endosc 2006;20:1208-13
   PubMed Web of Science ®Google Scholar
• Schwartz J, Leber MD, Gilli S, et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003;72:94-8
   PubMed Web of Science ®Google Scholar
• Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72-7
   PubMed Web of Science ®Google Scholar
• Crary S, Buchanan GR. Vascular complications after splenectomy for haematological disorders. Blood 2009;114:2861-8
   PubMed Web of Science ®Google Scholar
• Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second line treatment. Blood 2012;120:960-9
   PubMed Web of Science ®Google Scholar
• Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9
   PubMed Web of Science ®Google Scholar
• Kuter D, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
   PubMed Web of Science ®Google Scholar
• Newland A, Cervinek L, Eggermann J, et al. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim: four European case studies (abstract 0237). Haemtologica 2010;96:98
   Google Scholar
• Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-40
   PubMed Web of Science ®Google Scholar
• Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009;3:57-62
   PubMedGoogle Scholar
• Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991;77:1884-93
   PubMed Web of Science ®Google Scholar
• Kumpel BM. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol 2008;154:1-5
   PubMed Web of Science ®Google Scholar
• Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment in immune thrombocytopenic purpura: a randomised, double blind, placebo-controlled trial. Lancet 2009;373:641-8
   PubMed Web of Science ®Google Scholar
• Coopamah MD, Freedman J, Semple JW. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-a receptor antagonist. Blood 2003;102:2862-7
   PubMed Web of Science ®Google Scholar
• Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000;95:2523-9
   PubMed Web of Science ®Google Scholar
• Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009;3:57-62
   PubMedGoogle Scholar
• Beliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FccRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008;41:109-19
   Google Scholar
• Neil S, Lipman LR, Jackson LJ, et al. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J 2005;46(3):258-68
   PubMed Web of Science ®Google Scholar
• Olovnikova1 NI, Ershler MA, Grigorieva OV, et al. Impact on N_glycosylation profile of monoclonal anti_D antibodies as a way to control their immunoregulatory and cytotoxic properties. Biochemistry (Moscow) 2012;77:925-33
   PubMed Web of Science ®Google Scholar
• Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689-700
   PubMed Web of Science ®Google Scholar